Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Buy
69
MESO Quote, Financials, Valuation and Earnings
Last price:
$19.39
Seasonality move
:
12.27%
Day range:
$18.95 - $19.90
52-week range:
$9.61 - $22.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
136.71x
P/B ratio:
4.97x
Volume:
437.2K
Avg. volume:
228.8K
1-year change:
16.23%
Market cap:
$2.5B
Revenue:
$17.2M
EPS (TTM):
-$0.85
Analysts' Opinion
-
Consensus RatingMesoblast Ltd. has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $35.00, Mesoblast Ltd. has an estimated upside of 79.67% from its current price of $19.48.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $35.00 representing 100% downside risk from its current price of $19.48.
Fair Value
-
According to the consensus of 1 analyst, Mesoblast Ltd. has 79.67% upside to fair value with a price target of $35.00 per share.
MESO vs. S&P 500
-
Over the past 5 trading days, Mesoblast Ltd. has overperformed the S&P 500 by 7.69% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Mesoblast Ltd. does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Mesoblast Ltd. revenues have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Mesoblast Ltd. reported revenues of --.
Earnings Growth
-
Mesoblast Ltd. has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Mesoblast Ltd. reported earnings per share of --.
Enterprise value:
2.5B
EV / Invested capital:
--
Price / LTM sales:
136.71x
EV / EBIT:
--
EV / Revenue:
147.51x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-44.27x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$5.7M
Return On Assets:
--
Net Income Margin (TTM):
-593.86%
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2022-06-30 | 2023-06-30 | |
| Income Statement | ||||||
| Revenue | $7.5M | $10.2M | $7.7M | $2.2M | $2.1M | |
| Gross Profit | -- | -- | -- | -$8.8M | -$6.5M | |
| Operating Income | -$107.5M | -$80.8M | -$68.8M | -$19.8M | -$18.7M | |
| EBITDA | -$87.7M | -$73M | -$58.5M | -- | -$17.3M | |
| Diluted EPS | -$1.55 | -$63.40 | -$51.23 | -$0.31 | -$0.27 | |
| Period Ending | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2025-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $148.2M | $69.8M | $81.7M | $86.5M | -- | |
| Total Assets | $824.9M | $750.4M | $669.4M | $669.2M | -- | |
| Current Liabilities | $94.3M | $51.4M | $42M | $73.2M | -- | |
| Total Liabilities | $243.5M | $253.3M | $167.6M | $188.8M | -- | |
| Total Equity | $581.4M | $497M | $501.8M | $480.4M | -- | |
| Total Debt | $94.2M | $96.6M | $108.8M | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-06-30 | 2024-06-30 | 2025-06-30 | 2024-06-30 | 2025-06-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -$55.5M | -$56.6M | -$48.5M | -- | |
| Cash From Investing | -- | -$96.6K | $120K | -$28K | -$440K | |
| Cash From Financing | -- | $47.3M | $154M | -$3M | -$4.8M | |
| Free Cash Flow | -$63.6M | -$55.8M | -$57.3M | -- | -- | |
MESO
Sector
Market Cap
$2.5B
$27.9M
Price % of 52-Week High
88.55%
51.04%
Dividend Yield
0%
0%
Shareholder Yield
-11.75%
-1.49%
1-Year Price Total Return
16.23%
-16.66%
Beta (5-Year)
2.025
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$18.54
200-day SMA
Buy
Level
$14.13
Bollinger Bands (100)
Buy
Level
14.85 - 17.73
Chaikin Money Flow
Buy
Level
32.7M
20-day SMA
Buy
Level
$17.62
Relative Strength Index (RSI14)
Buy
Level
67.03
ADX Line
Buy
Level
20.71
Williams %R
Sell
Level
-12.0863
50-day SMA
Buy
Level
$16.84
MACD (12, 26)
Buy
Level
0.72
25-day Aroon Oscillator
Buy
Level
80
On Balance Volume
Neutral
Level
144.2M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.576)
Buy
CA Score
(Annual)
Level (0.2643)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (0.2247)
Buy
Piotroski F Score
(Annual)
Level (6)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Silviu Itescu on June 8, 2004 and is headquartered in Melbourne, Australia.
Stock Forecast FAQ
In the current month, MESO has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MESO average analyst price target in the past 3 months is $35.00.
-
Where Will Mesoblast Ltd. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Mesoblast Ltd. share price will rise to $35.00 per share over the next 12 months.
-
What Do Analysts Say About Mesoblast Ltd.?
Analysts are divided on their view about Mesoblast Ltd. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Mesoblast Ltd. is a Sell and believe this share price will drop from its current level to $35.00.
-
What Is Mesoblast Ltd.'s Price Target?
The price target for Mesoblast Ltd. over the next 1-year time period is forecast to be $35.00 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is MESO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Mesoblast Ltd. is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of MESO?
You can purchase shares of Mesoblast Ltd. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Mesoblast Ltd. shares.
-
What Is The Mesoblast Ltd. Share Price Today?
Mesoblast Ltd. was last trading at $19.39 per share. This represents the most recent stock quote for Mesoblast Ltd.. Yesterday, Mesoblast Ltd. closed at $19.48 per share.
-
How To Buy Mesoblast Ltd. Stock Online?
In order to purchase Mesoblast Ltd. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get MESO Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
MESO
Sector
P/E ratio
--
23.85x
PEG ratio
--
-0.01x
P/B ratio
4.97x
1.81x
Price / LTM sales
136.71x
1.58x
Growth Metrics
MESO
Sector
Revenue growth
--
4.62%
Earnings growth
--
10.7%
Revenue (5-year growth)
-11.49%
6.5%
Earnings forecast
--
-$0.21
Profitability
MESO
Sector
Profitability FY 2025
$5.7M
$3.6M
Return on invested capital
--
-31.87%
Return on assets
--
-28.18%
Return on equity
--
-37.63%
Earnings Date
Last Earnings Date
Aug
28
Next Earnings Date
Feb
24
Estimated Next Earnings Date
Nov
27
Balance Sheet
MESO
Sector
Total cash
$37.7M
$26.4M
Short term investments
--
$25.7M
Total assets
$784.7M
$76.9M
Long term debt
--
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 22
Lamb Weston Holdings, Inc. [LW] is down 2.59% over the past day.
Buy
54
BMRN alert for Dec 22
BioMarin Pharmaceutical, Inc. [BMRN] is down 3.03% over the past day.
Buy
82
RKLB alert for Dec 22
Rocket Lab Corp. [RKLB] is up 9.97% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
